Prelude Therapeutics (NASDAQ:PRLD) is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.
Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations. The company’s second clinical-stage asset, PRT543, is a first-in-class, reversible inhibitor of protein arginine methyltransferase 5 (PRMT5) under evaluation for hematologic malignancies and solid tumors. Prelude is also advancing preclinical candidates targeting KRAS mutations and additional oncogenic drivers to build a diversified portfolio of precision oncology assets.
Headquartered in Cambridge, Massachusetts, Prelude Therapeutics collaborates with academic institutions, biopharmaceutical partners and contract research organizations to support global clinical trial efforts. Its integrated research and development capabilities span medicinal chemistry, structural biology, translational pharmacology and biomarker-driven clinical strategy, accelerating the progression of targeted cancer therapies toward the clinic.
Since its founding in 2017, Prelude has concentrated on delivering therapies for patient populations with high unmet medical need. With a management team boasting extensive oncology drug development, regulatory and commercial experience, the company seeks to bring differentiated precision medicines to individuals with hard-to-treat and treatment-resistant malignancies worldwide.
